arrow
C

Christopher R. Cabanski

Parker Institute for Cancer Immunotherapy
H指数:25
被引数:3,314

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer

泛血液学癌症对嵌合抗原受体 (CAR) T细胞治疗反应的预测生物标志物

2026-03-090
PRE
Immune biomarkers of response and resistance to ipilimumab and nivolumab in metastatic castration-resistant prostate cancer

对伊匹木单抗和纳武利尤单抗在转移性去势抵抗性前列腺癌中的应答和耐药免疫生物标志物

2026-01-010
OA
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer
2024-08-270
OAAI
Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma
2024-07-092
OAAI
Evaluating nivolumab (nivo) plus ipilimumab (ipi) in patients with metastatic castration-resistant prostate cancer (mCRPC): Clinical and translational results from the AMADEUS prostate expansion cohort
2024-04-050
PRE
Randomized placebo-controlled, biomarker-stratified phase 1b microbiome modulation trial for metastatic melanoma demonstrates impact of antibiotic pre-conditioning regimen on the microbiome and immunity
2024-04-050
PRE
Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity

黑色素瘤中随机安慰剂对照、生物标志物分层Ib期微生物组调节: 抗生素预处理对微生物组和免疫的影响

2024-04-032
OAAI
EXPLORATORY PLATFORM TRIAL TO EVALUATE IMMUNOTHERAPY COMBINATIONS WITH CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC PANCREATIC ADENOCARCINOMA (REVOLUTION)
2022-11-070
OA
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial

Sotigalimab和/或nivolumab联合化疗一线转移性胰腺癌: 来自PRINCE随机2期试验的临床和免疫学分析

2022-06-03170
OAAI
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses
2022-01-2429
OAAI
MULTIOMIC BIOMARKER SIGNATURES IDENTIFY SUBSETS OF PATIENTS WHO MAY BENEFIT FROM EITHER NIVOLUMAB OR SOTIGALIMAB IN COMBINATION WITH CHEMOTHERAPY IN METASTATIC PANCREATIC CANCER
2021-11-100
OA
A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects

一项1期随机研究,用于评估健康受试者中潜在的新型抗纤维化小分子GDC-3280的安全性,耐受性和药代动力学

2021-08-015
OAAI
The clonal evolution of metastatic colorectal cancer
2020-06-1250
OAAI
Long non-coding RNA RAMS11 promotes metastatic colorectal cancer progression
2020-05-0187
OAAI
A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients
2019-07-0164
PRE
Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study
2018-08-01127
OAAI